Problems associated with management of pre-invasive lesions

Breast Cancer Research

Volumn 5, Issue 6, 2003, Pages 309-312

  Purushotham, Anand D ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Breast; Management; Pre invasive disease

Indexed keywords

TAMOXIFEN;

AGE DISTRIBUTION; AXILLARY LYMPH NODE; BREAST HYPERPLASIA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CARCINOMA IN SITU; CLINICAL TRIAL; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; FAMILY HISTORY; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE DISSECTION; RECURRENCE RISK; REVIEW; SURGICAL TECHNIQUE; TREATMENT INDICATION; TUMOR VOLUME; BREAST; BREAST TUMOR; CANCER INVASION; FEMALE; HYPERPLASIA; PAGET NIPPLE DISEASE; PATHOLOGY; RISK FACTOR;

BREAST; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; HYPERPLASIA; NEOPLASM INVASIVENESS; RISK FACTORS;

EID: 0642275621     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr649     Document Type: Review

References (25)

1. Holland R, Veling SH, Mravunac M, Hendriks JH: Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985, 56: 979-990.
2. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998, 16:441-452.
3. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, Van Dongen JA: Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000, 355:528-533.
4. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, Mignotte H, Fichet V, Fay R, Servent V, Giard S, Charra-Brunaud C, Lemanski C, Auvray H, Jacquot S, Charpentier JC: Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 2002, 53: 868-879.
5. Chan KC, Knox WF, Sinha G, Gandhi A, Barr L, Baildam AD, Bundred NJ: Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer 2001, 91:9-16.
6. Lagios MD, Silverstein MJ: Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies. Surg Oncol Clin N Am 1997, 6:385-392.
7. Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B, McNeese M, Pierce LJ, Landmann C, Olivotto IA, Borger J, Kim J, de la Rochefordiere A, Schultz DJ: Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys 2001, 50:991-1002.
8. Vicini FA, Recht A: Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol 2002, 20:2736-2744.
9. Szelei-Stevens KA, Kuske RR, Yantsos VA, Cederbom GJ, Bolton JS, Fineberg BB: The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiation therapy or by mastectomy. Int J Radiat Oncol Biol Phys 2000, 48:943-949.
10. Hiramatsu H, Bornstein BA, Recht A, Schnitt SJ, Baum JK, Connolly JL, Duda RB, Guidi AJ, Kaelin CM, Silver B, Harris JR: Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: possible importance of family history. Cancer J Sci Am 1995, 1:55-61.
11. Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, Hutson L, Peltz E, Whitehead G, Reintgen D, Cantor A: Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001, 67:513-519.
12. Klauber-DeMore N, Tan LK, Liberman L, Kaptain S, Fey J, Borgen P, Heerdt A, Montgomery L, Paglia M, Petrek JA, Cody HS, Van Zee KJ: Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000, 7:636-642.
13. Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS: Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000, 7:15-20.
14. Bijker N, Peterse JL, Fentiman IS, Julien JP, Hart AA, Avril A, Cataliotti L, Rutgers EJ: Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer 2002, 87:615-620,
15. Silverstein MJ, Lagios MID, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, Poller DN: A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996, 77:2267-2274.
16. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000.
17. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
18. IBIS investigators: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
19. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352:98-101.
20. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998, 352:93-97.
21. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N: Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001, 28: 400-418.
22. Tocino I, Garcia BM, Carter D: Surgical biopsy findings in patients with atypical hyperplasia diagnosed by stereotaxic core needle biopsy. Ann Surg Oncol 1996, 3:483-488.
23. Renshaw AA, Cartagena N, Schenkman RH, Derhagopian RP, Gould EW: Atypical ductal hyperplasia in breast core needle biopsies. Correlation of size of the lesion, complete removal of the lesion, and the incidence of carcinoma in follow-up biopsies. Am J Clin Pathol 2001, 116:92-96.
24. Shin SJ, Rosen PP: Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med 2002, 126:697-701.
25. Jacobs TW, Connolly JL, Schnitt SJ: Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am J Surg Pathol 2002, 26:1095-1110.